This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Hyperplasia of prostate
  • /
  • Silodosin: a review of its use in the treatment of...
Journal

Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.

Read time: 1 mins
Published:1st Feb 2015
Author: Keating GM.
Source: Drugs
Ref.:Drugs. 2015 Feb;75(2):207-17.
DOI:10.1007/s40265-014-0344-z.

Silodosin is a highly selective α1A-adrenoceptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Oral silodosin had a rapid onset of effect in men with lower urinary tract symptoms (LUTS) associated with BPH, with improvements seen in voiding and storage symptoms, maximum urinary flow rate and health-related quality of life in well-designed, 12-week trials. Silodosin was noninferior to tamsulosin in terms of improving LUTS associated with BPH. The efficacy of silodosin was maintained in 9-month extension studies and was also seen in a phase IV study conducted in a real-world setting. Silodosin was generally well tolerated and was associated with a low risk of orthostatic hypotension. Abnormal ejaculation was the most commonly reported adverse event, although few patients discontinued treatment with silodosin because of this adverse event. In conclusion, silodosin is a useful option for the treatment of LUTS associated with BPH.

Read abstract on library site